[ad_1]
FILE PHOTO: A screen shows the course of action of pharmaceutical manufacturer AbbVie on the floor of the New York Stock Exchange on July 18, 2014. REUTERS / Brendan McDermid
(Reuters) – AbbVie Inc. announced on Friday that its cancer treatment combined with chemotherapy agents did not achieve the primary goal of an advanced-stage study of patients with diabetes. a form of pancreatic cancer.
The treatment, Imbruvica, did not show a statistically significant improvement in progression-free survival or overall survival of patients with metastatic pancreatic cancer, compared to the combination of placebo and two chemotherapy.
The American Cancer Society estimates that pancreatic cancer accounts for about 3% of all cancers in the United States and about 7% of all cancer deaths, and predicts that 56,770 people will be diagnosed with pancreatic cancer by 2019.
Imbruvica, sold together with Johnson and Johnson, is an oral drug that targets an enzyme called Bruton tyrosine kinase and blocks the function of certain cancer cells.
The drug has improved the survival of patients with blood cancer as part of a separate terminal study conducted in December.
Imbruvica, which generated $ 2.57 billion in revenue for AbbVie in 2017, was approved for the first time in November 2013 and is used to treat several forms of cancer, including mantle cell lymphoma and lymphoid leukemia chronic.
The drug is currently approved by the US Food and Drug Administration in six disease areas with nine treatment indications, AbbVie said.
Report by Aakash Jagadeesh Babu in Bengaluru; Edited by Maju Samuel
Source link
